Theravance Biopharma (TBPH) EBIAT (2016 - 2025)
Theravance Biopharma (TBPH) has disclosed EBIAT for 13 consecutive years, with $3.6 million as the latest value for Q3 2025.
- On a quarterly basis, EBIAT rose 128.47% to $3.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $29.3 million, a 158.88% increase, with the full-year FY2024 number at -$15.5 million, up 71.87% from a year prior.
- EBIAT was $3.6 million for Q3 2025 at Theravance Biopharma, down from $54.8 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $54.8 million in Q2 2025 to a low of -$86.5 million in Q1 2021.
- A 5-year average of -$19.1 million and a median of -$15.6 million in 2023 define the central range for EBIAT.
- Peak YoY movement for EBIAT: crashed 41.88% in 2024, then soared 431.75% in 2025.
- Theravance Biopharma's EBIAT stood at -$35.3 million in 2021, then soared by 64.68% to -$12.5 million in 2022, then rose by 28.23% to -$9.0 million in 2023, then crashed by 73.49% to -$15.5 million in 2024, then skyrocketed by 123.28% to $3.6 million in 2025.
- Per Business Quant, the three most recent readings for TBPH's EBIAT are $3.6 million (Q3 2025), $54.8 million (Q2 2025), and -$13.6 million (Q1 2025).